These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 30791097)
21. Clinical usefulness of CEA, CA19-9, and CYFRA 21-1 as tumor markers for urothelial bladder carcinoma. Washino S; Hirai M; Matsuzaki A; Kobayashi Y Urol Int; 2011; 87(4):420-8. PubMed ID: 22041857 [TBL] [Abstract][Full Text] [Related]
22. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. Bidard FC; Hajage D; Bachelot T; Delaloge S; Brain E; Campone M; Cottu P; Beuzeboc P; Rolland E; Mathiot C; Pierga JY Breast Cancer Res; 2012 Feb; 14(1):R29. PubMed ID: 22330883 [TBL] [Abstract][Full Text] [Related]
23. CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. Nakamura T; Ide H; Eguchi R; Hayashi K; Takasaki K; Watanabe S Dis Esophagus; 2017 Nov; 11(1):35-39. PubMed ID: 29040480 [TBL] [Abstract][Full Text] [Related]
24. Monitoring of therapy in head and neck patients during the radiotherapy by measurement of Cyfra 21-1. Pradier O; Hille A; Schmiberger H; Hess CF Cancer Radiother; 2002 Feb; 6(1):15-21. PubMed ID: 11899676 [TBL] [Abstract][Full Text] [Related]
25. Relationship between pretreatment levels of serum Cyfra 21.1, CEA and PET metabolic parameters in NSCLC. Dogan I; Karyagar S; Karyagar SS; Kahraman C; Alver A Ann Nucl Med; 2014 Nov; 28(9):829-35. PubMed ID: 24990528 [TBL] [Abstract][Full Text] [Related]
26. [Usefulness of the SCC, CEA, CYFRA 21.1, and CRP markers for the diagnosis and monitoring of cervical squamous cell carcinoma]. Chmura A; Wojcieszek A; Mrochem J; Walaszek-Gruszka A; Deja R; Masłyk B; Bartnik W; Sodowski K Ginekol Pol; 2009 May; 80(5):361-6. PubMed ID: 19548456 [TBL] [Abstract][Full Text] [Related]
27. Extramammary Paget's disease: treatment, prognostic factors and outcome in 76 patients. Hatta N; Yamada M; Hirano T; Fujimoto A; Morita R Br J Dermatol; 2008 Feb; 158(2):313-8. PubMed ID: 18028492 [TBL] [Abstract][Full Text] [Related]
28. MiR-155, a potential serum marker of extramammary Paget's disease. Guo H; Qi RQ; Sheng J; Liu C; Ma H; Wang HX; Li JH; Gao XH; Wan YS; Chen HD BMC Cancer; 2018 Nov; 18(1):1078. PubMed ID: 30458743 [TBL] [Abstract][Full Text] [Related]
29. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study. Lumachi F; Lo Re G; Tozzoli R; D'Aurizio F; Facomer F; Chiara GB; Basso SM Anticancer Res; 2014 Nov; 34(11):6663-7. PubMed ID: 25368272 [TBL] [Abstract][Full Text] [Related]
30. Extramammary Paget disease. Part I. epidemiology, pathogenesis, clinical features, and diagnosis. Shah RR; Shah K; Wilson BN; Tchack M; Busam KJ; Moy A; Leitao MM; Cordova M; Neumann NM; Smogorzewski J; Nguyen KA; Hosein S; Dafinone M; Schwartz RA; Rossi A J Am Acad Dermatol; 2024 Sep; 91(3):409-418. PubMed ID: 38704032 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion. Lai RS; Chen CC; Lee PC; Lu JY Jpn J Clin Oncol; 1999 Sep; 29(9):421-4. PubMed ID: 10563194 [TBL] [Abstract][Full Text] [Related]
32. Neutrophil-to-lymphocyte ratio is a potential prognostic biomarker for extramammary Paget disease: A retrospective study. Maeda T; Uehara J; Toyoshima R; Nakagawa T; Yoshino K J Dermatol; 2022 Nov; 49(11):1188-1192. PubMed ID: 35903974 [TBL] [Abstract][Full Text] [Related]
33. Cytokeratin fragment 19 (CYFRA 21-1) and carcinoembryonic antigen for early prediction of recurrence of lung adenocarcinoma. Kao CH; Hsieh JF; Ho YJ; Ding HJ Lung; 1999; 177(5):333-7. PubMed ID: 10467024 [TBL] [Abstract][Full Text] [Related]
35. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy. Sone K; Oguri T; Nakao M; Kagawa Y; Kurowaka R; Furuta H; Fukuda S; Uemura T; Takakuwa O; Kanemitsu Y; Ohkubo H; Takemura M; Maeno K; Ito Y; Sato H; Muramatsu H; Niimi A Anticancer Res; 2017 Feb; 37(2):935-939. PubMed ID: 28179355 [TBL] [Abstract][Full Text] [Related]
36. Screening values of carcinoembryonic antigen and cytokeratin 19 fragment for lung cancer in combination with low-dose computed tomography in high-risk populations: Initial and 2-year screening outcomes. Triphuridet N; Vidhyarkorn S; Worakitsitisatorn A; Sricharunrat T; Teerayathanakul N; Auewarakul C; Chungklay N; Krongthong W; Luengingkasoot S; Sornsamdang G; Patumanond J; Sritipsukho P Lung Cancer; 2018 Aug; 122():243-248. PubMed ID: 30032839 [TBL] [Abstract][Full Text] [Related]
37. Clinical and pathological characteristics of extramammary Paget's disease: report of 246 Chinese male patients. Kang Z; Zhang Q; Zhang Q; Li X; Hu T; Xu X; Wu Z; Zhang X; Wang H; Xu J; Xu F; Guan M Int J Clin Exp Pathol; 2015; 8(10):13233-40. PubMed ID: 26722523 [TBL] [Abstract][Full Text] [Related]
38. The expression of HER-2 in extramammary Paget's disease. Masuguchi S; Jinnin M; Fukushima S; Makino T; Sakai K; Inoue Y; Igata T; Ihn H Biosci Trends; 2011 Aug; 5(4):151-5. PubMed ID: 21914949 [TBL] [Abstract][Full Text] [Related]
39. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer. Nakata B; Takashima T; Ogawa Y; Ishikawa T; Hirakawa K Br J Cancer; 2004 Aug; 91(5):873-8. PubMed ID: 15280913 [TBL] [Abstract][Full Text] [Related]
40. Serum level of cytokeratin 19 fragment (CYFRA 21-1) indicates tumour stage and prognosis of squamous cell carcinoma of the oesophagus. Tsuchiya Y; Onda M; Miyashita M; Sasajima K Med Oncol; 1999 Apr; 16(1):31-7. PubMed ID: 10382940 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]